summari report result expect
result larg in-lin expect updat model
reflect stronger weaker perform us drug base
im trend see pharma tracker start page
overal outlook littl chang forecast sale
ep vs consensu respect
expect initi guidanc conserv base
acquisitions/divestitur sale growth guidanc report
growth flattish expect continu target
earn grow faster sale see oper ep
growth reason model sale
organ growth ep oper growth
consensu respect model includ
headwind fx lifescan/asp divestitur
factor may fulli reflect consensu outlook
lower price target ep
record specif
like larg in-lin base jnj guidanc
ytd perform estim impli organ sale
guidanc high-end rang
believ time gener zytiga entri absenc gener
tracleer competit help im data point overal us
pharma perform in-lin slightli
forecast forecast take account headwind gross-to-
net adjust although yet quantifi impact
see organ sale growth expect
medic devic consum sale growth acceler
estim lifescan/asp divestitur add
medic devic growth continu roll new babi care
brand improv consum growth estim organ sale
growth medic devic consum
see pharma growth slow due gener zytiga
biosimilar remicade/procrit competit aggreg see
overal growth organ guidanc perhap toward
lower half rang start fx headwind
dilut divestitur expect report sale
flat slightli sale estim
consensu forecast exclud
recent close ci acquisit increas report
sales/growth boost margin
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani data secur llc estim reuter
continu previou page
ep expect outpac sale growth impact asp divestitur unclear lower
ep growth report oper estim includ
fx drag dilut lifescan/asp divestitur headwind may fulli reflect
consensu ep model includ ci acquisit add oper
incom like reduc incom import assumpt model incom
flattish mean need replac gain sale lifescan
meaning declin net incom hard overcom view due multipl
headwind know yet recogn gain asp sale includ could
increas net incom boost ep like exceed current consensu expect
howev also recogn investor would prefer see incom line declin rather
increas investor perceiv line lower qualiti earn compar oper incom
unclear us new cfo wolk approach issu guid januari
talc litig remain manag view talcum powder litig investor
focus compani juli high-profil loss talc litig juri award
women includ punit damag appeal case preced larg
product liabil case suggest reward reduc figur jnj talc litig histori
success far case complet appeal dismiss mistrial outright
win overturn win appeal case includ juli decis still appeal
guidanc impli growth deceler guid organ sale growth
guidanc coupl report ytd organ growth impli organ growth
meaning slowdown earlier year slowdown attribut entri gener
zytiga competit although believ guidanc may prove somewhat conserv given
gener competit began least month later expect addit absenc gener
tracleer competit may also contribut addit strength howev jnj
anticip gross-to-net adjust pharma accrual rebat anticip
repres headwind depress growth compani quantifi impact
adjust assum materi enough manag call
us pharma could better model consum may bit lighter report
result estim total sale organ ep compar
consensu respect analysi im data suggest like upsid us
forecast stelara zytiga imbruvica tracleer partli off-set potenti soft invega
sustenna/trinza xarelto sale updat forecast product fulli
adjust potenti upsid due uncertainti impact adjust
magnitud adjust modest could upsid new us pharma sale
forecast estim organ pharma sale growth vs growth
deceler primarili reflect impact gener zytiga consum estim organ
growth vs ex-babi launch stock analysi nielsen data point
growth us consum estim note tough us consum comp due
restock post-hurrican maria prior year period model slightli faster organ growth
estimpli compani report secur llc estim report organ growth defin ex-fx johnson johnson
medic devic vs reflect compani expect growth continu
improv despit tougher comp final forecast assum fx
headwind littl chang month ago
updat us pharmaceut sale forecast base im trend analysi im data
jnj key us drug suggest potenti upsid us pharmaceut sale although potenti
impact adjust remain unknown factor figur base im analysi rais
us sale forecast stelara zytiga
imbruvica tracleer lower us sale
estim xarelto invega sustenna/trinza
im data also point potenti upsid drug like remicad invokana chang
estim due uncertainti impact rebating/discount furthermor believ jnj
adjust accrual rebat may impact product competit
market like remicad xarelto forecast us pharmaceut sale yr/yr vs
organ growth ytd estim gener zytiga account least
slower growth monthli product tracker detail start page
major price increas price increas earli rais price across much
us drug portfolio saw major price increas rest
estim averag price increas jnj top us drug account
us pharma sale accord recent media report reuter rais price across
pharmaceut portfolio recent mostli rang consist compani
histor price action expect much price increas net discounts/fe etc
emphas volum rather price key driver strong growth
consum growth expect deceler nielsen data trend forecast
jnj ww consum sale averag organ growth first three quarter
improv growth due easier comp resolut hurrican maria-rel
suppli disrupt jnj us consum busi analysi aggreg nielsen data
suggest sale growth estim report
figur out-performance reflect stock associ babi care brand relaunch
benefit believ could roll captur nielsen also note tougher comp
due benefit post-hurrican recoveri prior year period nielsen data appear trend
direct in-lin report us consum sale organ growth time figur
ww basi forecast consum sale organ growth includ us sale
compani report secur llc estim organ growth adjust fx acquisitions/divestitur sell day prior price adjust pharma venezuela anima exit pharma overal growth adjust remicad rebat ex-adjust organ growth pharma overal cardiovascular cerenovu neurovascular intervent solut start diabet adjust anima exit impact amo acqusit includ ex-fx growth rate atln acquisit includ ex-fx growth rate key busi segmentsorgan growth ex-fx growth medic technolog
nielsen sale base aggreg data
nielsen sale base aggreg data
summari outlook
expect organ sale growth forecast organ sale growth
deceler estim guidanc slower growth larg due
growth deceler pharma primarili due us gener zytiga competit began late
see discuss manag state previou investor confer pharma
busi grow in-lin market year estim compani
expect growth improv medic devic consum segment see growth
acceler least medic devic divestitur lifescan asp busi
see improv consum sale growth driven on-going relaunch babi care brand
put piec could see guid organ sale growth although
guidanc may toward lower half rang start figur forecast exclud impact
recent acquisit ci hold could improv report sale oper margin
growthnielsen estimate report organ growth nielsen estimate reportedour estmkt compani report secur llc estim organ growth report ex-fx adjust sell day differ venezuela impact prior period price johnson johnson
estim report sale flattish slightli report basi estim
total sale yr/yr consensu yr/yr figur
model assum fx headwind exclud revenu lifescan sold asp
expect sale close lifescan sale approxim repres
growth headwind year close oct estim asp revenu approxim
growth headwind view higher consensu sale forecast like
fulli account factor aggreg growth headwind model
jnj pharma growth slow like closer market model organ
pharma sale growth estim report
adjust key contributor slower growth gener zytiga began
impact gener competit like modest expect due time entri
see impact unchang also know launch gener version zytiga
could help somewhat minim loss brand zytiga sale estim us zytiga sale fall
yr/yr declin zytiga repres growth headwind
pharma overal addit expect continu biosimilar procrit
eros forecast sale fall yr/yr also model continu biosimilar eros
remicad us sale declin yr/yr final assum us gener tracleer entri
earli sale fall nearli year gener delay recent
launch like erleada tremfya potenti new launch esketamin boost pharma
growth none product larg enough yet entir off-set generic/biosimilar headwind
expect pharma growth reacceler strong in-market portfolio robust
pipelin believ remain well posit grow pharma busi market
beyond manag also clear point reacceler pharma sale growth
market level beyond jnj pharmaceut analyst day may provid
color longer term pipelin addit anniversari gener zytiga entri end
remov major growth headwind head follow year
see medic devic sale growth acceler sinc may analyst day
manag consist talk improv sale growth medic devic md busi
vs expect md growth outpac market suggest busi
grow least in-lin market exit estim divestitur lifescan
diabet asp advanc steril product togeth add md growth suggest
growth acceler realist base portfolio manag addit expect
new product launch help improve/stabil growth knee spine busi
model organ sale growth md vs estim
consum growth also expect improv similarli expect consum busi
start outpac market growth estim consum organ sale growth
estim consum growth driven continu global relaunch
babi care brand began note model reflect pend ci deal
announc octob plan buy remain busi yet
sale mm lowmidhighour report sale organ growth underli lifescan asp oper oper fx headwind report report compani report factset secur llc estim report organ growth defin ex-fx medic technolog
transact move consolid ci sale jnj top-lin help improv
overal consum sale growth lower ci incom book incom line
expect oper ep growth still outpac revenu growth model ep
consensu ep repres report yr/yr growth ahead
top-lin growth organ report gener expect ep growth faster
sale goal believ remain intact oper basi exclud fx estim
jnj ep growth closer includ dilut divestitur lifescan
asp figur believ consensu forecast fulli account magnitud fx
headwind dilut divestitur note recent investor meet latest tax reform
updat materi affect tax rate outlook compani also note busi
china mostli immun trade war impact china tariff repres
sale margin headwind
net incom remain key question key assumpt model net
incom remain stabl vs guidanc includ gain sale
lifescan believ need replac gain sale lifescan least maintain
net incom flattish achiev ep growth assumpt meaning declin net
incom hard overcom view due number headwind like
divestitur dilut gener zytiga zytiga high margin possibl off-set lifescan
sale gain potenti gain sale asp although know yet recogn gain
much gain flow bottom-lin illustr purpos gain asp sale
add increment jnj net incom estim increment ep
contribut suffici off-set divestiture-rel dilut
uncertainti account gain asp sale recent year includ gain asset
sale incom way off-set ep dilut divestur exampl
recogn pre-tax gain divestitur nucynta/ sale cordi
incom howev alway case exampl report
pre-tax gain sale ocd exclud benefit non-gaap result due magnitud
gain recogn gain asp divestitur non-gaap result expect see net
incom exceed vs guidanc net ep benefit
gain would help off-set fx headwind divestitur dilut also mitig dilut
gener zytiga/tracl biosimilar remicade/procrit howev higher net incom ep
impact would also make difficult comparison recogn gain sale
non-gaap result could see net incom fall repres anoth
drag ep believ would difficult overcom top headwind
program decemb follow reuter stori talcum powder litig led signific
pressur stock believ complet buy-back rel quickli thu
benefit estim annual earn accret model assum
buy-back complet around addit jnj strong cash posit
numer earn headwind could see compani announc addit repurchas program
epslowmidhighour report ep organ underli lifescan asp oper oper fx report ep compani report factset secur llc estim assum deal close earli johnson johnson
perhap larger size year expect guid conserv usual start
year room potenti upsid year progress figur
lower price target base updat sotp analysi lower price
target reflect recent chang peer group valuat believ
consum medic devic unit continu trade modest discount peer group
due slower sale growth despit slower expect return above-
market growth thu see modest premium peer group valuat still warrant
figur largest product liabil award us juri
guidanc actualguid actualfx chang tailwind tw headwind hw increas hw decreas plu tax chang hw tw tw decreas compani report secur llc estim repres initi compani guidanc repres midpoint guidanc rang ep growthreport ep onsegmentprofit ep devic project use estimate discount averag kbm pg premium averag discount averag snn zmh group estim first callsourc factset secur llc estim growth pro forma atln fwdshare sale cagrcaseiniti awardpost-verdict resultengl reynold philip morri reynold johnson johnson pendingboeken philip morri depuy orthoped johnson kart wyeth texa bloomberg secur llc medic technolog
us remicad sale seem in-lin base im trend forecast us remicad ex-export
sale yr/yr declin larg consist report sale declin
ytd ex-reb adjust ytd estim appear conserv im
analysi impli us remicad sale could exceed use recent histor ratio
report sale im sale howev histor ratio fluctuat past year
greater biosimilar eros part due chang rebating/discount chang
remicad estim extrapol im sale show declin yr/yr compar declin
ytd declin
biosimilar remicad ramp appear flattish im sale show biosimilar remicad ramp remain
modest total sale increas juli januari august
novemb figur entri second biosimilar month ago seem acceler
pace biosimilar penetr trail averag remicad im sale remain
differ report im sale continu widen suggest increas rebat
discount pfe/celltrion inflectra still account biosimilar remicad im sale
biosimilar procrit competit underway impact like limit pfe biosimilar
procrit retacrit launch im sale show retacrit sale decemb compar
procrit sale month alreadi assum biosimilar procrit competit
guidanc impact seem mute like remain near-term base
im data suggest us darzalex sale larg in-lin forecast model
us darzalex sale yr/yr forecast consist extrapol im sale
suggest report sale larg in-lin estim ww
basi believ sale estim track jnj partner genmab recent announc
receipt mileston trigger darzalex sale reach next key catalyst
darzalex approv maia data front-lin use us split-dos regimen
expect longer term on-going phase studi subq formul
significantli reduc infus time expand patient access therebi help maintain darzalex
growth momentum beyond accord brandimpact darzalex held share
line mm market novemb novemb drug first approv
line figur line darzalex maintain lead share novemb figur
darzalex held overal market share survey despit share front-lin use
increas us imbruvica revenu estim increas us imbruvica revenu
esim impli end-us sale forecast upgrad
base stronger-than-expect im sale trend suggest sale also updat
guidanc us imbruvica sale wich impli revenu year
rx perspect roll imbruvica volum grew weekli
averag figur phase imbruvica mono- combo therapi data differ
patient popul watch wait patient expect emerg reinforc drug
benefit front-lin use
ou imbruvica sale may also modestli exceed forecast partnership
book us sale book ou sale two split global profit call
rasi us imbruvica sale guidanc ww imbruvica revenu
respect abbv ou revenu estim impli end-us sale
sale vs estim
invokana franchis rx volum declin appear eas modestli forecast us invokana
sale yr/yr q/q forecast appear somewhat conserv compar
extrapol im sale closer chang forecast howev given modest
magnitud potenti upsid jnj pend adjust expect product
competit categori like invokana impact invokana franchis monthli trx
volum fell yr/yr oct/nov slight improv vs declin prior quarter figur
weekli im data first three week decemb also show slower yr/yr nrx volum
declin stabl sequenti rx volum figur
start slower rx volum declin appear coincid somewhat stop
credenc renal outcom trial earli base posit efficaci find around time
also present data real-world analysi suggest increas risk below-the-kne
lower extrem amput invokana vs diabet drug howev
unclear posit updat drive stabl invokana rx volum recent month
note afeti data credenc still remain big unknown clean safeti profil credenc
slide
may encourag fda consid remov black box warn invokana labl may
help turnaround invokana sale time
invokana/invokamet nrx share fell may januari although pace
share loss appear moder comparis azn farxiga/xiguo xr share
remain stabl around ytd bi/lli jardianc franchis share climb
januari novemb figur jardianc mark share dobul past two year
driven posit data label updat base empa-reg outcom trial show
drug lower cardiovascular risk increas amputation/fractur risk quarterli growth
overal categori rel stabl mid- high-singl digit rang past year
rais us zytiga sale estim increas us zytiga sale estim
base extrapol im sale time gener entri mid-decemb
month later anticip result higher zytiga sale
extrapol im sale suggest zytiga sale similar sale rang
believ gener entri regardless exact time like still led addit discount
possibl rebat accrual could lower report zytiga sale also note
launch jnj gener zytiga may also contribut zytiga revenu jnj
guidanc assum gener zytiga entri expect compani abosrb increment
headwind like consensu alreadi account gener zytiga model
erleada launch momentum continu exit month sinc launch us erleada sale
annual base im sale monthli erleada rx volum continu grow
nrx volum also increas albeit slower pace estim us erleada sale
appear reason base im data note competitor xtandi approv
indic us juli
see downsid risk us xarelto sale earli tell compass impact
lower xarelto sale forecast yr/yr revis base
extrapol im sale suggest sale rang see rebating/discount
continu play import role competit market could make histor reported/im
sale ratio less reliabl addit given competit market believ xarelto could one
product affect adjut would lower report sale monthli trx nrx
volum show yr/yr growth oct/nov ytd growth figur overal
novel oral anticoagul noac market growth novemb eliqui maintain lead
among noac share m/m follow xarelto share
m/m past year xarelto lost nearli share point eliqui gain share figur
noac account oral anticoagul nrx vs end
xarelto launch figur fda approv compass data mid-octob expand
xarelto use includ cad/pad coronari arteri disease/peripher arteri diseas howev
earli tell new indic help xarelto recaptur share and/or reacceler growth
us invega sustenna/trinza sale could weaker lower us sale forecast
flattish yr/yr extrapol im sale suggest report sale may
low rang note monthli im sale sustenna trinza trend lower
past two consecut month novemb sale drug actual lower yr/yr result
im sale jnj long-act inject atyp laia franchis sustenna trinza risperd consta
fell oct/nov well mid- high-teen growth trend seen thu far figur
us laia market maintain sizeabl lead franchis nrx market share
past month ostuka abilifi maintena hold share yr/yr
aristada share yr/yr figur
rais us stelara sale forecast base im trend increas us stelara
sale yr/yr growth updat base encourag extrapol
im sale suggest report sale approach recent histori point fairli stabl
reported/im sale ratio suggest im sale trend may reason indic report sale
stelara im sale grew oct/nov ytd suggest continu momentum
product despit strong uptak tremfya figur trx volum specialti suggest crohn
remain key growth driver monthli written gastroenterolog specialist stelara
rose past year rheumatologist deceler low-
to-mid-singl digit declin earlier year dermatologist stelara
approv ulcer coliti could help maintain stelara growth momentum
us tremfya sale in-lin forecast us tremfya sale
extrapol im sale suggest report sale approxim
year half market tremfya im sale annual nearli base
novemb data comparison nv cosentyx lli taltz sale annual
first year market current cosentyx im sale annual taltz im
sale annual weekli tremfya volum appear track in-lin stelara remain
behind cosentyx taltz time post-launch figur im may still underestim
true tremfya uptak due exclus free sampl data continu view tremfya
import growth driver jnj pharma franchis although expect drug cannib stelara
sale among dermatologist time note newest competitor ilumya sun pharma
appear gain much traction three month market
sale yr/yr growth seem reason base extrapol im sale
suggest sale similar rang oct/nov simponi im sale grew yr/yr aria im sale
grew togeth drive franchis growth slightli acceler im
sale growth figur
us pah sale could exceed estim opsumit tracleer uptravi figur togeth
account us pah peripher arteri hypertens sale extrapol im suggest
potenti upsid opsumit tracleer estim although ratio report im
sale choppi addit believ gener tracleer competit may immin
could accrual rebat adjust estim us opsumit sale
yr/yr growth compar extrapol im sale uptravi
estim us sale growth howev extrapol im data suggest sale closer
tracleer rais us sale estim yr/yr
absenc gener competit although im data suggest us tracleer sale may closer
sale rais forecast due possibl adjust
analysi independ arriv secur llc basi data
inform im respons relianc recipi either data analys
compris mostli pfe/celltrion inflectra
figur darzalex hold posit line multipl myeloma market
reportedim reportedimsreportedim us split im health incorpor nation sale perspect compani report secur llc estim sale estim base commentari im data forecast us imbruvica sale assum record end-us sale report consist third month perform prior quarter assum decemb im sale repres im sale remicadebiosimilar remicad medic technolog
figur darzalex maintain lead line multipl myeloma market
follow chang imbruvica ndc nation drug code im report doubl count rx
one distributor late march spike nrx volum april late may suggest us
report issu persist im current look data
figur invokana franchis continu lose share
figur zytiga erleada monthli volum growth
rx y/i present canva data ada meet -posit efficaci safeti trade-off strengthen warn risk acut kidney add black box warn leg foot amput market share invokana invokamet jardianc synjardi glyxambi azn farxiga xigduo growthmonthli trxtrx growthtrx volumezytiga latitud data jun launch feb medic technolog
new oral anticoagul includ pradaxa xarelto eliqui savaysa
 nrxnrxoral anticoagulantsnew oral anticoagul new oral anticoagul xarelto spaf approvedeliqui spaf approvedeliqui dvt prevent approvedsavaysa spaf approvedeliqui dvt treatment approvedxarelto dvt treatment growthim sale sustenna trinza consta sale yoy im sale growthsustenna launch aug launch jun market sharealk aristadaotsuka abilifi maintenajnj sinvega sustenna trinza risperd consta medic technolog
figur stelara im sale fall growth slow recent
figur atln opsumit im sale growth continu
figur atln tracleer im sale continu declin
figur atln uptravi im sale remain solid launch trajectori
price target
price target impli cash ep base sum-of-the-
part analysi risk includ delay pipelin product unexpect delay deal integr
unexpect deterior industri
expect growth slow due multipl headwind see growth re-acceler
johnson johnson world comprehens broadli base healthcar compani
consum pharmaceut medic devic market medic devic segment consist primarili
product cardiovascular orthoped surgic vision compani report sale
year-over-year organ basi
